INTRODUCTION
============

Cerebral ischemic events (CIE) are a leading cause of death and morbidity in the United States with limited treatment options in the acute setting.[@b1-wjem12_2p0227]--[@b6-wjem12_2p0227] This type of central nervous system injury has been associated with hemodynamic perturbation secondary to myocardial injury and dysfunction but the mechanisms underlying this relationship are poorly understood.[@b5-wjem12_2p0227]--[@b7-wjem12_2p0227] Cardiac dysfunction in cerebral ischemia patients may have significant contributions in the pathogenesis of this disease. Within the territory of tissue affected by the ischemic insult, intrinsic autoregulation of the vasculature is lost rendering cerebral blood flow directly dependent upon cardiac output and contractility.[@b8-wjem12_2p0227],[@b9-wjem12_2p0227]

The relationship between cerebral blood flow and cardiac contractility in the acute presentation of patients with acute cerebral ischemia has not been comprehensively evaluated. Our objective in this preliminary, retrospective study was to evaluate the relationship between left ventricular systolic function and transcranial doppler (TCD) peak systolic velocities (PSV) in patients with CIEs defined either as an acute ischemic stroke (AIS) or transient ischemic attack (TIA).

METHODS
=======

The Institutional Review Board for human research approved the study protocol and procedures. We conducted a retrospective chart review of CIE patients identified by our institutions TCD registry.[@b10-wjem12_2p0227] We included patients based on the following criteria: adult patients admitted within 24 hours of onset of a focal neurological deficit, record of both an echocardiogram and TCD performed within 72 hours of admission, and a discharge diagnosis of an AIS or TIA. Our exclusion criteria included age less than 18 years old, the presence of cerebral hemorrhage on initial neuro-imaging, or defined imaging parameters on echocardiography which could confound results. Echocardiogram exclusion criteria included the inability to measure the cardiac ejection fraction (EF) or the presence of severe left-sided stenotic or regurgitant valvular lesions that could potentially alter cardiac output.

Additionally, given that certain TCD vessel distributions are technically more difficult to measure, we established a quality control measure to exclude individual vessel distributions from analysis if PSV or pulsatility index (PI) measurements could not be acquired in greater than 50% of patients. PSV vessel distributions included the middle cerebral artery, anterior cerebral artery, posterior cerebral artery, internal carotid artery, ophthalmic artery and vertebral artery. We measured PIs only in the middle cerebral and vertebral artery territories.

A senior resident investigator, under the supervision of senior faculty investigators, used a standardized method of data collection to extract demographic and clinical data onto a data collection form. Echocardiogram reports were read by staff cardiologists and reviewed for the measured EF and the presence of severe left-sided stenotic or regurgitant valvular lesions. We considered an EF below 50% abnormal.[@b11-wjem12_2p0227]

TCD studies in the registry were read by one of the investigators, a staff neurologist certified in neurosonology, and extracted by the senior resident investigator in a supervised and standardized fashion from the electronic medical record. We reviewed PSVs in the following vessel distributions: middle cerebral artery, anterior cerebral artery, posterior cerebral artery, internal carotid artery, ophthalmic artery and vertebral artery. We reported one PSV for each territory of the cerebral vasculature. We calculated the mean PSV for each vessel territory by combining the left and right PSV values in all patients. We performed the calculation this way because the PSV reference range for left and right vessel territories is identical and prior literature has demonstrated PSV and PI responsiveness in both sides of the middle cerebral artery territory to cardiac augmentation in the setting of AIS.[@b12-wjem12_2p0227]--[@b14-wjem12_2p0227]

Similarly, we measured the PI for each territory of the middle cerebral artery and vertebral artery, and calculated their means. We did not measure PIs in other vessel distributions.

Prior literature has documented PSV and PI to correlate with cerebral blood flow.[@b14-wjem12_2p0227]--[@b20-wjem12_2p0227] For our primary analysis, we stratified patients into low (EF\<50%) and normal (EF≥50%) contractility groups and calculated the mean PSV for each group. We performed a comparison of means using an unpaired t-test with statistical significance of the two-tailed P value being less than 0.05.

We reported the other results as the mean, standard deviation and 95% confidence interval where indicated. We used Fisher's Exact Test in sub-group analysis comparing demographical differences between groups. We indicated statistical significance by an alpha error \<0.05.

RESULTS
=======

We identified 197 TCD studies during from March to October 2003. Of these studies, 127 were excluded for including neurosurgical patients (n=63), neurology patients with conditions other than CIEs (n=37), and other patient populations (n= 27). We identified 70 CIE patients with both TCD studies and echocardiograms performed during their hospitalization. However, we excluded 12 of these patients because the TCD and echocardiogram were not performed within the first 72 hours of admission, or because echocardiograms revealed severely stenotic or regurgitant left-sided valvular abnormalities. Thus, 58 patients fulfilled our inclusion and exclusion criteria and were included into the study cohort.

In the identified 58 patients, 81.1% (n=47) had a hospital discharge diagnosis of AIS and 18.9% (n=11) had a diagnosis of TIA. Demographics of our patient population are summarized in ([Table](#t1-wjem12_2p0227){ref-type="table"}). Male patients made up 67.2% of patients. The mean age was 65.0 ± 14.8. The most common co-morbidities were hypertension (51.7%), diabetes (25.9%) and hyperlipidemia (25.9%). Within the cohort, 10.3% of patients previously had an AIS or TIA and 10.3% of patients had a prior history of congestive heart failure. The mean initial NIH stroke scale for identified patients was 10.77 ± 7.29 (95% CI 7.54 to 14.00). The mean initial systolic blood pressure for patients was 168.7 mmHg ± 37.2 (95% CI 157.6 mmHg to 179.9 mmHg). The mean initial heart rate was 83.6 ± 16.7 (95% CI 78.4 to 88.7).

Of the total sample of patients, 24.1% (n=14) had evidence of systolic dysfunction with an EF below 50% on echocardiography, and the rest, 75.8% (n=44), had normal systolic function. Among patients with systolic dysfunction 14.3% (n=2) had a hospital discharge diagnosis of TIA. In the group with normal cardiac function 20.4% (n=9) had a hospital discharge diagnosis of TIA (p=1.0, Fisher's Exact Test).

For TCD quality control, we ensured an adequate amount of PSV and PI measurements for each vessel distribution. We found that all vessel distributions met our quality threshold except for PSV measurements in the posterior cerebral artery distribution. We were only able to obtain 50.0% (n=29) of those measurements and therefore excluded the posterior cerebral artery vessel distribution from analysis. We performed PSV measurements for the middle cerebral artery distribution in 91.4% of patients (n=53), the anterior cerebral artery in 86.2% (n=50), the internal carotid in 88.0% (n=51), the ophthalmic artery in 69.0% (n=40), and the vertebral artery in 96.6% (n=56). For PI measurements, 91.4% (n=53) had middle cerebral artery PI measurements, and 96.6% (n=56) had vertebral artery PI measurements.

The mean PI in patients with normal systolic function (EF ≥50%) compared to those with systolic dysfunction (EF \< 50%) was as follows: middle cerebral artery 1.07 ± 0.35 vs. 1.19 ± 0.41, p=0.23; vertebral artery 1.18 ± 0.34 vs 1.21 ± 0.28, p=0.62. We did not measure PIs in any other vessel distributions.

The mean PSV in patients with normal systolic function (EF ≥50%) compared to those with systolic dysfunction (EF \< 50%) was as follows ([Figure](#f1-wjem12_2p0227){ref-type="fig"}): middle cerebral artery 62.0 ± 28.6 cm/s vs. 51.0 ± 23.3 cm/s, p=0.11; anterior cerebral artery 52.1 ± 21.6 cm/s vs. 45.9 ± 22.7 cm/s, p=0.28; internal carotid artery 56.5 ± 20.1 cm/s vs. 46.4 ± 18.4 cm/s, p=0.04; ophthalmic artery 18.6 ± 7.2 cm/s vs. 15.3 ± 5.2 cm/s, p=0.11; vertebral artery 34.0 ± 13.9 cm/s vs. 31.6 ± 15.0 cm/s, p=0.44.

DISCUSSION
==========

A significant proportion (13--28%) of patients with cerebral ischemia may have impaired cardiac contractility either at baseline from existing congestive heart failure or as part of the pathogenesis of the disease.[@b21-wjem12_2p0227]--[@b23-wjem12_2p0227] The latter pathogenic mechanisms include catecholamine induced stunning or direct neuro-inhibition secondary to the ischemic insult.[@b24-wjem12_2p0227],[@b25-wjem12_2p0227] Our data suggests that cerebral blood flow (based on mean TCD PSV) in the internal carotid artery vascular territory is higher in acute cerebral ischemia patients with preserved left ventricular contractility. Additionally, we observed a trend towards higher cerebral blood flow among patients with preserved cardiac contractility in the territories of the middle cerebral artery, anterior cerebral artery, ophthalmic artery and vertebral artery. These findings serve to strengthen the limited existing animal literature and human pilot studies evaluating the impact of cardiac function on cerebral blood flow.

Nearly two decades ago Keller et al[@b8-wjem12_2p0227] demonstrated in a primate model that cerebral blood flow in both ischemic and non-ischemic brain regions correlates with cardiac output. Soon afterwards, Korosue et al[@b26-wjem12_2p0227] observed a 29% mean increase in cardiac output in ischemic stroke patients with isovolemic hemodilution associated with increases in regional cerebral blood flow.

More recently, Treib et al[@b14-wjem12_2p0227] performed a pilot study with hypervolemic hemodilution combined with dopamine or dobutamine infusion in 24 stroke patients with middle cerebral artery occlusions. They measured the influence of blood pressure and cardiac output on the TCD PSV in a single intracranial vessel, the middle cerebral artery. With therapy there was a 53% increase in cardiac output. In the unaffected hemisphere, there was a 27% increase in the systolic velocity. On the side of the lesion, there was an 11% increase. The relative diminished response on the affected side was believed to have been due to thrombus burden or counterregulatory pathways causing vasoconstriction. Additionally, they observed an increase in PI by 46% in the affected and 47% in the unaffected hemisphere. This differed from our study since we did not observe significant PI differences between the low and normal EF groups. A significant difference between our studies is that Treib et al's[@b14-wjem12_2p0227] patients received infusions of dopamine or dobutamine.

A translational question of important consideration is whether cardiac contractility correlates with functional neurological outcome. It is unknown if undifferentiated systolic dysfunction promotes expansion of the ischemic penumbra, or conversely whether hyperdynamic cardiac function enhances the risk of hemorrhagic transformation. Although relatively uninvestigated, Korosue et al[@b26-wjem12_2p0227] reported modest increases in neurological scores with cardiac output augmentation. Subsequent isovolemic hemodilution studies were not supportive, but to our knowledge they did not record cardiac output values.[@b27-wjem12_2p0227] No other studies have reported improved functional outcome with cardiac augmentation or hemodynamic optimization. Additionally, we found no studies relating higher cerebral hemorrhage rates to hemodynamic augmentation or hyperdynamic states.[@b28-wjem12_2p0227],[@b29-wjem12_2p0227]

Nevertheless, in the stroke rehabilitation literature, Kevorkian et al[@b30-wjem12_2p0227] observed better functional recovery in acute stroke patients with normal cardiac contractility. Their design differed from ours as they stratified acute stroke patients into severely depressed (EF\<35%) and moderately depressed or normal (EF≥35%) contractility cohorts. The latter group had higher hospital discharge functional scores and higher rates of functional status improvement from admission to discharge. While the authors conceded their study had several limitations, their results suggest that acute stroke patients with preserved systolic function may have better functional outcomes than those with severe systolic dysfunction.

Thus, it remains unclear which subgroups of cerebral ischemia patients could potentially benefit from cardiac output augmentation as suggested by prior authors.[@b31-wjem12_2p0227] Beyond impaired contractility, it is well-known that subgroups of cerebral ischemia patients may have serum troponin elevation and arrhythmias --- which have been related to higher in-hospital mortality rates.[@b21-wjem12_2p0227],[@b24-wjem12_2p0227],[@b32-wjem12_2p0227],[@b33-wjem12_2p0227] Currently there is a paucity of investigators evaluating the incidence, role, underlying mechanisms, and impact of myocardial and hemodynamic derangements in the setting of cerebral ischemia. The future development of adjunctive evidence-based hemodynamic guidelines is critical.

LIMITATIONS
===========

A principle limitation of this study was the retrospective design and small sample size. In addition, echocardiograms performed by technicians in our institution's cardiovascular lab were susceptible to user variability. Another limitation was the heterogeneity of the defined CIE population. While there are neurovascular, physiologic and management differences between AIS and TIA patients, we postulated that the merging of these populations would not significantly impact our results for the sake of this preliminary analysis. For example, at our institution all AIS and TIA patients have echocardiograms and a cerebral vascular study performed prior to discharge. There are overlapping co-morbidities between each population, including diabetes, hypertension and hyperlipidemia. National AIS and TIA guidelines have overlapping recommendations for management, and at our institution AIS and TIA patients were admitted to the same clinical floors and clinician teams.[@b34-wjem12_2p0227],[@b35-wjem12_2p0227] Thus, given the overlapping characteristics of stroke and TIA patients, we thought that the relation between cerebral flow velocities and cardiac function would be preserved.

Another limitation of our study was that we did not know the prior EF of patients to delineate the underlying mechanism for systolic dysfunction. It is possible that patients with elevated catecholamine levels from neuro-endocrine activation could potentially have myocardial stunning and other cerebrovascular perturbations that could alter echocardiogram findings and other variables measured in this study.

A methodological limitation of the retrospective design was that TCDs and echocardiograms were performed within 72 hours of admission, rather than simultaneously. Our study was also susceptible to selection bias since many patients undergoing TCDs may have had contraindications to magnetic resonance imaging or magnetic resonance angiography. Another limitation was that the majority of patients in our study did not have concomitant cerebral angiography performed in order to localize vascular occlusions in the AIS patients. Thus, our mean PSV or PI values could have been impacted if a patient had a partial or total occlusion of one of the large vessels being measured by TCD. For example, a patient could have a middle cerebral artery occlusion contrasted to a stroke syndrome caused by a more distal occlusion in the M1 or M2 portion of the middle cerebral artery territory. While our methodology to calculate the mean PSV or PI would help to mitigate this issue, it is a limitation that we were unable to control for given the information in the medical records and the fact that the majority of these patients did not have cerebral angiography performed.

CONCLUSION
==========

Cerebral blood flow in the internal carotid artery territory as measured by the mean PSV in cerebral ischemia patients appears to be higher in those with preserved left ventricular contractility. Future research is necessary to better understand the impact of myocardial contractility on cerebral blood flow in patients with acute cerebral ischemia.
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###### 

Demographics of patient population.

  **Demographic**                                 **Number**   **Percentage**
  ----------------------------------------------- ------------ ----------------
  Male                                            39           67.2
  Hypertension                                    30           51.7
  Hyperlipidemia                                  15           25.9
  Diabetes                                        15           25.9
  Congestive heart failure                        6            10.3
  Coronary artery disease/myocardial infarction   7            12.1
  Stroke/transient ischemic attack                6            10.3
  Tobacco use                                     4            6.9
  Atrial fibrillation                             3            5.2
  Respiratory disease                             2            3.4
  Hemodialysis/renal insufficiency                2            3.4
  Seizure                                         1            1.7
  Cancer                                          1            1.7
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